You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

New Antidiabetic Drug in Three Preparations

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000430229.99197.75
Drug Watch
Abstract

* Alogliptin (Nesina) is the newest dipeptidyl peptidase-4 inhibitor approved for the treatment of type 2 diabetes. It's also available as part of two combination therapies—called Kazano when combined with metformin and Oseni when combined with pioglitazone.

* The most common adverse effects are upper respiratory infections, nasopharyngitis, and headache. Alogliptin may also cause acute pancreatitis, severe liver disease, and severe allergic reactions. Hypoglycemia is possible if the drug is administered with a sulfonylurea or with insulin.

Author Information

Diane S. Aschenbrenner is the course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch: daschen1@jhu.edu.

© 2013 Lippincott Williams & Wilkins, Inc.